Evidence map›Paper›PMID 35354825›Full record

ArticleScientific data2022

A comprehensive LFQ benchmark dataset on modern day acquisition strategies in proteomics.

Bart Van Puyvelde, Simon Daled, Sander Willems, Ralf Gabriels, Anne Gonzalez de Peredo, Karima Chaoui, Emmanuelle Mouton-Barbosa, David Bouyssié, Kurt Boonen, Christopher J Hughes and 8 more

Abstract readDataset
In one paragraph

Article in Scientific data, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Carafe enables high qualitybioRxiv : the preprint server for biology · 2025
    Article
  14. Article
  15. Article
  16. TIMSJournal of proteome research · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Bart Van PuyveldeProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.ORCID 0000-0002-7368-1762
Simon DaledProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.
Sander WillemsDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Ralf GabrielsVIB-UGent Center for Medical Biotechnology, VIB, 9000, Ghent, Belgium.ORCID 0000-0002-1679-1711
Anne Gonzalez de PeredoInstitut de Pharmacologie et de Biologie Structural (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.ORCID 0000-0001-6152-6311
Karima ChaouiInstitut de Pharmacologie et de Biologie Structural (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.
Emmanuelle Mouton-BarbosaInstitut de Pharmacologie et de Biologie Structural (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.
David BouyssiéInstitut de Pharmacologie et de Biologie Structural (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.ORCID 0000-0002-0847-4759
Kurt BoonenVITO Health, Mol, Belgium.
Christopher J HughesWaters Corporation, Wilmslow, UK.
Lee A GethingsWaters Corporation, Wilmslow, UK.
Yasset Perez-RiverolEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK.ORCID 0000-0001-6579-6941
Nic BloomfieldSCIEX, Concord, Ontario, Canada.
Stephen TateSCIEX, Concord, Ontario, Canada.
Odile SchiltzInstitut de Pharmacologie et de Biologie Structural (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.
Lennart MartensVIB-UGent Center for Medical Biotechnology, VIB, 9000, Ghent, Belgium.ORCID 0000-0003-4277-658X
Dieter DeforceProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.
Maarten DhaenensProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium. maarten.dhaenens@ugent.be.

Funding

Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 11B4518NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 12E9716NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1S50918N
6 · The paper itself

Abstract

In the last decade, a revolution in liquid chromatography-mass spectrometry (LC-MS) based proteomics was unfolded with the introduction of dozens of novel instruments that incorporate additional data dimensions through innovative acquisition methodologies, in turn inspiring specialized data analysis pipelines. Simultaneously, a growing number of proteomics datasets have been made publicly available through data repositories such as ProteomeXchange, Zenodo and Skyline Panorama. However, developing algorithms to mine this data and assessing the performance on different platforms is currently hampered by the lack of a single benchmark experimental design. Therefore, we acquired a hybrid proteome mixture on different instrument platforms and in all currently available families of data acquisition. Here, we present a comprehensive Data-Dependent and Data-Independent Acquisition (DDA/DIA) dataset acquired using several of the most commonly used current day instrumental platforms. The dataset consists of over 700 LC-MS runs, including adequate replicates allowing robust statistics and covering over nearly 10 different data formats, including scanning quadrupole and ion mobility enabled acquisitions. Datasets are available via ProteomeXchange (PXD028735).

Indexed as

BenchmarkingProteomicsAnimalsChromatography, LiquidHumansMass SpectrometryProteomeProteome

Identifiers

PMID35354825
PMCPMC8967878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.